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Lowering of low-density lipoprotein (LDL) cholesterol is accepted as a key objective in the prevention of cardiovas-
cular disease.1,2 Controversies remain, however, as to which 
kind of subjects to treat, the use of goals, the magnitude of 
the benefit, and potential harms, especially in the context of 
primary prevention.3–6 Examination of the long-term (lifetime) 
consequences of lowering LDL cholesterol can assist greatly 
in understanding more fully the efficacy and safety of this 
intervention, and a number of studies have reported extended 
observations beyond the end of the formal trial.7–11 In the 
West of Scotland Coronary Prevention Study (WOSCOPS), 
in which follow-up was first examined ≈10 years after the end 
of the 5-year trial,7 there was evidence of further reduction in 
coronary events over the 15-year period and, as indicated by 
the available data, no emergent safety issues. Overall, there 
was a reduction in all-cause mortality (hazard ratio [HR]=0.88; 
95% confidence interval [CI], 0.79–0.99; P=0.03) and in the 
outcome of death or hospitalization for coronary heart dis-
ease (HR=0.75; 95% CI, 0.68–0.83; P<0.001). Furthermore, 
over the 15-year period, treatment with pravastatin for 5 years 
was shown to be cost-saving in terms of overall health ser-
vice costs,12 adding an important economic dimension to the 
clinical outcome analysis. Previous work had shown that there 
was a relatively low uptake of statin treatment in the first 5 
years of extended follow-up after the trial, which means that 
WOSCOPS is uniquely placed to investigate the legacy effects 
of 5 years of statin treatment in terms of ongoing benefit and 
potential safety issues later in life.
Clinical Perspective on p 1080
We have now increased the period of follow-up to 20 years 
to examine a range of mortality and morbidity outcomes as 
a first event and as a total burden of disease in the form of 
cumulative hospital admissions. More detailed interrogation 
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of hospitalization rates has allowed a fuller picture of benefits 
and risks to emerge. Given a mean age at randomization of 55 
years, the extended observation period to a mean of 75 years 
(range, 65–84 years) gives an approximation of the lifetime 
benefit of this pharmacological intervention.
Methods
The design of WOSCOPS and its long-term follow-up have been 
described elsewhere.13–15 It was a randomized trial of pravastatin (40 
mg once daily) versus placebo in men 45 to 64 years of age (mean 
age, 55 years) with raised cholesterol who had no evidence of previous 
myocardial infarction (based on medical history and a baseline, cen-
trally read ECG). Participants had a mean±SD plasma cholesterol level 
of 272±23 mg/dL (7.0±0.6 mmol/L) and a mean±SD LDL cholesterol 
level of 192±17 mg/dL (5.0±0.44 mmol/L); 44% were current smok-
ers; 16% had a history of hypertension; and 1% had a history of diabe-
tes mellitus. Between 1989 and 1991, 6595 men gave written informed 
consent and were enrolled in the trial. The average follow-up was 4.9 
years (range, 3.5–6.1 years), with final study visits in May 1995.
After the end of the trial, use of lipid-lowering therapy during the 
first 5 years of extended follow-up was monitored by review of case 
records. In the original pravastatin and placebo groups, 28.6% and 
24.3% at 1 year after the trial, 33.6% and 29.4% at 3 years, and 38.7% 
and 35.2% at 5 years, respectively, were found to be on statins.7 
No further data on statin treatment were available after this point. 
Extended follow-up for clinical events was based entirely on linkage to 
national electronic hospital discharge records held by the Information 
Services Division in Edinburgh, the Scottish Cancer Registry, and the 
Scottish General Register Office death records by means of estab-
lished methods.16,17 Data were extracted from the beginning of the 
trial to October 2011 and classified with International Classification 
of Diseases codes and Office of Population, Censuses and Surveys 
Classification of Surgical Operations and Procedures codes. Cancer 
Registry Data were available only until November 2010.
The original trial was approved by the ethics committees of the 
University of Glasgow and participating health boards in Scotland, 
and the long-term follow-up and associated record linkage were 
approved by the ethics committee of the Glasgow Royal Infirmary 
and the Privacy Advisory Committee of the National Health Service 
for Scotland. All participants gave informed consent to take part in 
the trial and for the examination of their medical records.
Previous analyses focused on time to first event for deaths, incident 
cancers, and composite cardiovascular outcomes7,14 and health eco-
nomics evaluation.12 In the present report, we assessed the impact on 
mortality, incident cancers, and cumulative number of hospital admis-
sions over 20 years or until death. We report hospital admissions for 
noncardiovascular causes, cardiovascular causes, coronary heart dis-
ease, myocardial infarction, heart failure, and stroke, and we describe 
the cumulative number of coronary revascularizations (coronary artery 
bypass graft, percutaneous coronary intervention, or angioplasty).
Statistical Methods
Cumulative incidence functions, accounting for the competing risk 
of death from other causes, were used to describe the incidence of 
cause-specific deaths or time to first incident cancer. To estimate 
treatment effects for cause-specific mortality and incident cancers, 
Cox proportional hazards models were fitted, including the treatment 
group and baseline risk factors of age, body mass index, systolic and 
diastolic blood pressures, high-density lipoprotein and LDL choles-
terol levels, log-transformed triglyceride level, nitrate use, history of 
angina, history of diabetes mellitus, history of hypertension (all yes or 
no), smoking status (current, former, never), and a 7-category social 
deprivation score.18 Treatment effects (pravastatin versus placebo) 
were expressed as HRs with 95% CIs and corresponding P values.
The cumulative numbers of hospital admissions of each type were 
presented without adjustment for the competing risk of death to repre-
sent the true difference in healthcare resource use over 20 years (all par-
ticipants had a potential follow-up of a minimum of 20 years). We also 
calculated the crude rates of hospital admission of each type, correcting 
for the different total periods of follow-up in each randomized group 
resulting from the increased survival and consequent greater exposure 
to risk in the statin-treated group. These statistics were compared with 
the use of rerandomization tests (based on 10 000 rerandomizations).
Because of the interest in the long-term impact of statin treatment 
on diabetes mellitus and its complications, we identified all noncardio-
vascular hospital admissions that were associated with diabetes mel-
litus or its complications either as a reason for admission or as a factor 
complicating the admission. Cardiovascular admissions were omitted 
from this analysis because of the potential bias associated with the 
overall reduction in cardiovascular admissions resulting from statin 
treatment. Similarly, we reported other noncardiovascular hospital 
admissions grouped by International Classification of Diseases, 10th 
Revision codes to examine the long-term safety of statin use. These 
analyses were further subdivided into day cases and non–day cases.
The data analysis was generated with SAS software, version 9.3 
of the SAS System for Windows (Cary, NC).
Table 1. Number of Events and HRs for Pravastatin 






  Deaths, n (%) 1253 (38.0) 1145 (34.7)
  HR (95% CI)* 0.87 (0.80–0.94)
  P value* 0.0007
All cardiovascular
  Deaths, n (%) 496 (15.1) 414 (12.5)
  HR (95% CI)* 0.79 (0.69–0.90)
  P value* 0.0004
CHD
  Deaths, n (%) 326 (9.9) 252 (7.6)
  HR (95% CI)* 0.73 (0.62–0.86)
  P value* 0.0002
Stroke
  Deaths, n (%) 86 (2.6) 103 (3.1)
  HR (95% CI)* 1.15 (0.86–1.53)
  P value* 0.35
All noncardiovascular
  Deaths, n (%) 757 (23.0) 731 (22.1)
  HR (95% CI)* 0.92 (0.83–1.02)
  P value* 0.12
Cancer
  Deaths, n (%) 469 (14.2) 468 (14.2)
  HR (95% CI)† 0.96 (0.84–1.09)
  P value† 0.49
CHD indicates coronary heart disease; CI, confidence interval; and HR, hazard 
ratio.
*Adjusted for age, body mass index, systolic and diastolic blood pressures, 
high- and low-density lipoprotein cholesterol, log triglycerides, nitrate use, 
history of angina, history of diabetes mellitus, history of hypertension, smoking 
status (current, ex-smoker, never), and deprivation (Carstairs category).
†Adjusted for age, body mass index, smoking status (current, ex-smoker, 
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Results
The mean follow-up until censoring date or death in the pravas-
tatin-treated group was 18.6 compared with 18.3 years for the 
placebo group. Baseline characteristics of the 2 randomized 
groups have been reported previously.15 There were no dif-
ferences in characteristics at baseline between the 2 groups, 
including age, body mass index, blood pressure, cholesterol, 
alcohol use, smoking, employment, and medical history.
Mortality
In the total follow-up period, 1253 (38%) of those originally 
randomized to placebo died compared with 1145 (34.7%) 
in the pravastatin group (HR=0.87; 95% CI, 0.80–0.94; 
P=0.0007). There were also reductions in cardiovascular mor-
tality (HR=0.79; 95% CI, 0.69–0.90; P=0.0004) and coronary 
mortality (HR=0.73; 95% CI, 0.62–0.86; P=0.0002) but not 
stroke. There was no evidence of an increased risk of non-
cardiovascular or cancer mortality in the pravastatin group 
(Table 1, Figure 1A–1D, and Figure Ia in the online-only Data 
Supplement).
Incident Cancers
There was no evidence of an increased risk of overall incident 
cancer (809 [24.6%] participants had events in the placebo-
treated group compared with 802 [24.3%] on pravastatin; 
P=0.24) or of cause-specific cancers (Table I and Figure Ib in 
the online-only Data Supplement).
Cumulative Hospital Admissions
In the group of 3293 participants originally randomized to 
placebo, 1546 experienced a total of 4102 cardiovascular 
admissions compared with 1398 participants (of 3302) in 
the pravastatin group who had 3436 admissions (P<0.0001; 
Table 2 and Figure 2A). Similarly, there were significant 
reductions in recurrent coronary (P=0.0006), myocardial 
infarction (P=0.0002), and heart failure (P=0.01) admissions 
(Figure IIa in the online-only Data Supplement and Figure 
2B–2C) but not stroke admissions (Figure IIb in the online-
only Data Supplement). There was a significant reduction 
in hospital admissions involving coronary revascularization 
(percutaneous coronary intervention, coronary artery bypass 
surgery or angioplasty), with 1210 events in the placebo 
group and 1029 in the pravastatin group (P=0.0078; Figure 
2D).
There were numerically more noncardiovascular admis-
sions in the pravastatin group, but after adjustment for duration 
of follow-up, the rates were similar (2.97 events in 10 years 
for placebo compared with 3.03 events in 10 years for pravas-
tatin). Neither comparison achieved statistical significance 
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Figure 1. Cumulative events over the 20-year follow-up period. Cumulative incidence functions are provided for the outcomes of death 
resulting from (A) all causes, (B) cardiovascular disease, (C) coronary heart disease, and (D) noncardiovascular disease. P values were 
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In a further exploration, hospitalizations were divided into 
day cases and non–day cases (ie, events involving an overnight 
stay). Subjects in the pravastatin group had fewer hospitaliza-
tions for cardiovascular reasons in both categories (Table 3). 
Tables II and III in the online-only Data Supplement give the 
frequency of noncardiovascular admissions by International 
Classification of Diseases body system classification for day 
cases and non–day cases. Overall, the numbers of subjects and 
cumulative events were balanced between the 2 groups for 
non–day cases. For day cases, it was noted that the pravastatin 
group had an apparent increased risk of events associated with 
diseases of the eye and adnexa (P=0.03 uncorrected for mul-
tiple comparisons), which was attributable for the most part 
to an excess of admissions for cataract surgery (not individu-
ally statistically significant). There were numerically more 
day-case events but not subjects with events associated with 
neoplasms and diseases of the digestive system.
Hospital Admissions Associated With Complications 
of Diabetes Mellitus
In the placebo group, a total of 221 participants experienced 
911 noncardiovascular hospital admissions that contained 
a diabetes-related International Classification of Diseases 
code compared with 201 participants (770 admissions) in 
the pravastatin-treated group (HR=0.81; 95% CI, 0.67–0.98; 
P=0.030). For hospital admissions involving complications of 
diabetes mellitus, 29 participants in the placebo group expe-
rienced 80 admissions compared with 12 participants (44 
admissions) in the pravastatin-treated group (HR=0.33; 95% 
CI, 0.16–0.66; P=0.0016). There were 23 deaths for which 
diabetes mellitus was given as the cause (15 patients on pla-
cebo and 8 patients on pravastatin).
Discussion
This 20-year follow-up of the WOSCOPS identified a con-
tinued legacy benefit from 5 years of LDL cholesterol low-
ering with a statin through improved survival resulting 
from decreased mortality from cardiovascular causes and 
an ongoing reduction in cardiovascular hospital admissions. 
Cumulative event rates are presented for both treatment arms 
to assess the impact of therapy on the total burden of disease. 
We observed a substantial and significant benefit: Cumulative 
event rates were 18% lower for cardiovascular disease and 
24% lower for myocardial infarction in the pravastatin group. 
Our focus on recurrent events reflects current interest in the 
impact of interventions on the total burden of disease. We 
also observed continuing divergence of the cumulative event 
curves for heart failure hospitalization over 20 years, with a 
35% lower rate in the pravastatin arm.
More than 2 decades since the publication of the first suc-
cessful primary prevention trial of a statin,15 with subsequent 
studies19,20 and meta-analyses5,21,22 also confirming the benefits 
of LDL cholesterol reduction, there are still concerns about 
side effects of treatment, long-term safety, impact on all-cause 
mortality, and cost-effectiveness3–6,23,24 that lead a number of 
commentators to continue to express caution when wider use 
of statins in primary prevention strategies is promoted.25,26 The 
present study found no increased incidence of cancer overall, 
and enhanced site-specific data show no imbalance between 
the 2 groups (Note the balanced rates for prostate cancer com-
pared with the previous report).7 Examination of noncardio-
vascular hospital admissions also showed no differences, with 
the exception of a possible increased risk of day-case hospital 
admissions associated with diseases of the eye for patients 
using pravastatin. The significance of this latter finding, which 
should be treated cautiously because of the borderline signifi-
cance and the multiple adverse effects investigated, lies in its 
link to historical concern that inhibition of cholesterol synthe-
sis would lead to risk of corneal opacity.27,28 Epidemiological 
studies have suggested both increased and decreased risk of 
cataracts linked to statin use.29–31 However, these studies will 
not have the length of follow-up available in WOSCOPS or 
the benefits of randomization in minimizing confounding 
factors. It should be noted that any treatment that improves 
cardiovascular survival will inevitably result in an increase in 
hospital admissions for noncardiovascular causes. We saw no 
evidence of this for non–day-case admissions. However, the 
trend toward increased day-case admissions, including treat-
ment for cancer but not number of participants with cancer, 
particularly for events associated with advancing age, in the 
later years of follow-up could be early evidence of this sur-
vival bias effect.
Table 2. Subjects With Events, Cumulative Recurrent 







Stroke Subjects with event, n 353 338
Events, n 589 562 0.60
Event rate† 0.098 0.091 0.62
MI Subjects with event, n 464 354
Events, n 538 419 0.0002
Event rate† 0.089 0.068 0.010
HF Subjects with event, n 123 91
Events, n 207 133 0.010
Event rate† 0.034 0.022 0.0020
CHD Subjects with event, n 958 800
Events, n 2286 1838 0.0006
Event rate† 0.38 0.30 0.0004
Any  
cardiovascular
Subjects with  
event, n
1546 1398
Events, n 4102 3436 <0.0001
Event rate† 0.68 0.56 0.0020
Noncardiovascular Subjects with  
event, n
2811 2828
Events, n 17 922 18 649 0.24
Event rate† 2.97 3.03 0.53
CHD indicates coronary heart disease; HF, heart failure; and MI, myocardial 
infarction.
*P values calculated with rerandomization tests.
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Reduction in heart failure as an outcome has been reported 
recently in a meta-analysis of 14 trials of statin-based LDL 
lowering with a risk reduction of 10%.32 The mean duration 
of observation in these studies was 4.3 years. Data presented 
here suggest that this additional clinical benefit may be under-
estimated in short-term studies, particularly in primary pre-
vention. As Preiss et al32 noted, we found that the number of 
heart failure admissions was reduced in subjects who had and 
in those who did not have an antecedent myocardial infarction 
(data not shown). The overall mechanism by which LDL low-
ering leads to a reduced incidence of heart failure is not fully 
clear. However, we note that much of the WOSCOPS follow-
up was before the use of troponin assays and certainly before 
newer high-sensitivity assays. Hence, many of the events clas-
sified as other coronary hospitalizations would today be clas-
sified as myocardial infarction. Likewise, the reduced need for 
revascularization in statin-treated participants indicates lower 
levels of ischemia, the repeated occurrence of which could be 
a mechanism for the development of heart failure.
We did not demonstrate a reduction in stroke at 20 years. 
There was no effect in the original trial,15 although we saw 
evidence of stroke reduction in the 15-year follow-up.7 
However, WOSCOPS was a primary prevention trial in rel-
atively young subjects compared with the majority of trials 
in the Cholesterol Treatment Trialists Collaborators (CTTC) 
analysis, which were secondary prevention studies in partici-
pants ≈10 years older at randomization and had shorter peri-
ods of follow-up.22 It is therefore difficult to compare directly 
the findings in CTTC with extended observations made when 
the original treatment arms are predicted to be receiving statin 
therapy at the same level after the trial.
In the assessment of the long-term impact of interven-
tions in primary prevention, it is essential that there is a 
balanced evaluation of the benefits resulting from reduction 
in cardiovascular events and the potential for adverse clini-
cal outcomes. Muscle-related side effects of statins have been 
studied in detail.33 They can lead to intolerance to the medica-
tion and, in rare instances, rhabdomyolysis.1,2 Statin therapy 
has also been shown in a number of studies to increase the 
propensity to develop type 2 diabetes mellitus,34,35 with an HR 
of ≈1.09 compared with placebo; a similar increase in diabetes 
risk is associated with the use of high- versus low-dose statin 
therapy.35 This is one of the issues raised by those concerned 
about the more widespread use of statins in the prevention of 
disease in lower-risk subjects.3–6 Diabetes mellitus is defined 
on the basis of blood glucose levels and is a disorder associ-
ated with macrovascular but also microvascular/noncardio-
vascular complications. Statins reduce cardiovascular disease, 
and it has been estimated that their use will prevent 5 inci-
dences of myocardial infarction for every new case of diabe-
tes mellitus.36 In this study, we were able to report that statin 
treatment was also associated over a 20-year follow-up with 
significantly fewer hospital admissions associated with non-
cardiovascular complications of diabetes mellitus. This raises 
the possibility that although statin use may affect blood glu-
cose levels, this does not necessarily translate into deleterious 
noncardiovascular pathologies. It should be noted, however, 
that WOSCOPS was unusual in that the incidence of type 2 
diabetes mellitus was lower in the actively treated arm during 
the original trial.37
There are limitations to this form of long-term follow-
up based on electronic health records as noted previously.7,16 
Critically, we do not know what lipid-regulating therapy was 
being used by the participants for the last 10 years of the 
study, and this limits the interpretation of data with regard 
to the magnitude of the 20-year benefit. If in the second half 
Placebo
Pravastatin
p < 0.0001 
Placebo
Pravastatin
p = 0.0002 
Placebo
Pravastatin






Figure 2. Cumulative numbers of hospital admissions for the outcomes of (A) cardiovascular disease, (B) myocardial infarction, (C) heart 




 http://ahajournals.org by on January 31, 2019
1078  Circulation  March 15, 2016
of the extended follow-up more subjects originally assigned 
to the placebo arm compared with the pravastatin arm were 
placed on a statin (as a result of having a coronary event or as a 
primary prevention measure by the general practitioner), then 
the difference in event rates between the 2 groups would be 
diminished, and the observed HR would be an underestimate 
of the long-term risk reduction attributable to statin therapy. 
In addition, we are dependent on the stability of the popula-
tion to allow comprehensive capture of hospitalizations within 
the healthcare information systems. However, Scotland is an 
area of relatively low social mobility after people reach mid-
dle age, which allowed us to achieve 100% follow-up at the 
end of the study. We also flagged all of our participants with 
the death registry in England and Wales and identified only 
15 deaths (0.6%) there from a total of 2398 deaths. We have 
no current method for identifying hospital admissions outside 
Scotland but do not feel this would have altered our findings. 
Finally, as a substantial number of participants die, analyses 
are complicated by competing risks.
Conclusions
In this primary prevention trial in high-risk men with ele-
vated LDL cholesterol but without a history of myocardial 
infarction, we observed a long-term legacy benefit of LDL 
lowering by statin therapy. Because over the 20 years the 
cohort aged from an average of 55 to 75 years, the cumula-
tive event rate is an estimate of the total burden of disease 
(more specifically of premature morbidity and mortality; 
male life expectancy in Scotland is 76.8 years), and the 
reduction in cardiovascular events is a measure of the life-
time benefit of the intervention. The reduction in cumulative 
cardiovascular events is substantial both numerically (with 
attendant economic savings) and in terms of relative risk 
(especially for heart failure). The observation that 5 years 
of statin therapy led to a prolonged risk reduction raises the 
issue that treatment might not need to be lifelong. That is, the 
legacy risk reduction after a 5- to 10-year treatment period 
may be sufficient to produce a clinically meaningful ben-
efit while limiting lifetime exposure to the drug. We cannot 
address this question fully using the information in the pres-
ent study, although it is clear that therapy would have to be 
maintained for subjects to experience maximum risk reduc-
tion because we saw a diminution in the treatment effect in 
the posttrial compared with the in-trial phases. The data on 
diabetes-associated noncardiovascular events indicate that 
further work is required to understand the clinical conse-
quences of the statin-induced increase in the incidence of 
this disorder. These long-term efficacy findings, particularly 
Table 3. Subjects With Events, Cumulative Recurrent Events, and Event Rates  








  CHD Subjects with event, n 452 391
Events, n 599 507 0.029
Event rate† 0.099 0.082 0.011
  All cardiovascular Subjects with event, n 661 594
Events, n 1018 845 0.048
Event rate† 0.169 0.137 0.34
  Noncardiovascular Subjects with event, n 2122 2259
Events, n 8521 9191 0.94
Event rate† 1.413 1.494 0.94
Non–day cases
  CHD Subjects with event, n 849 713
Events, n 1687 1331 0.0002
Event rate† 0.280 0.216 0.0008
  Any cardiovascular Subjects with event, n 1391 1234
Events, n 3084 2591 0.0004
Event rate† 0.512 0.421 0.0006
  Noncardiovascular Subjects with event, n 2406 2431
Events, n 9401 9458 0.54
Event rate† 1.559 1.537 0.54
CHD indicates coronary heart disease; HF, heart failure; and MI, myocardial infarction.
*P values calculated with rerandomization tests.
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on all-cause mortality, and detailed safety data should allay 
concerns over strategies to promote the more widespread use 
of statins in the population.
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CLINICAL PERSPECTIvE
Adoption of statin therapy for the primary prevention of cardiovascular disease is an area of controversy in clinical practice. 
There is perceived uncertainty about long-term efficacy with respect to vascular and all-cause mortality and the long-term 
safety of treatment. The findings of the present study should help alleviate at least some of these concerns. Extended follow-
up of this primary prevention trial in high-risk men with raised low-density lipoprotein cholesterol but without a history of 
myocardial infarction demonstrated a long-term legacy benefit of low-density lipoprotein lowering by statin therapy with a 
significant reduction in cardiovascular mortality and improved survival when viewed over the entire 20 years of follow-up. 
Furthermore, the reduction in cumulative cardiovascular events, representing the total burden of disease, was substantial 
both numerically (with attendant economic savings) and clinically in terms of relative risk across a range of cardiovascular 
outcomes. The finding of a late posttrial benefit of a reduced risk of heart failure gives further impetus to the need to start 
treatment early. These long-term efficacy findings, particularly for all-cause mortality, and detailed safety data should allay 
concerns over strategies to promote the more widespread use of statins in the population.
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